This report describes the hematopoietic stem cell transplantation (HSCT) activity in Europe in 2006 by indication, donor type and stem cell source. It illustrates differences compared to previous years and concentrates on the use of cord blood transplants. In 2006, there were 25 050 first HSCT, 9661 allogeneic (39%), 15 389 autologous (61%) and 3690 additional re-or multiple transplants reported from 605 centers in 43 participating countries. Main indications were leukemias (7963 (32%; 85% allogeneic)); lymphomas (14 169 (56%; 89% autologous)); solid tumors (1564 (6%; 95% autologous)); nonmalignant disorders (1242 (5%; 90% allogeneic)) and non-classified 'others' (112 (1%)). There was an increase in allogeneic HSCT of 9% when compared to 2005, while autologous HSCT numbers remained similar. There were 544 allogeneic cord blood HSCT, which corresponds to 5% of all allogeneic HSCT. The majority, 67%, were used for patients with leukemia. The highest percentage of cord blood transplants, 27%, was seen for inherited disorders of metabolism. No autologous cord blood transplants were reported. The highest increase in allogeneic HSCT was observed for AML, which comprises 31% of all allogeneic HSCT. Numbers of autologous HSCT remained similar in most main indications. This data provide an update of the current HSCT experience in Europe. Bone Marrow Transplantation (2008) 41, 687-705; doi:10.1038/sj.bmt.1705956; published online 17 December 2007 Keywords: hematopoietic stem cell transplantation; Europe; transplant rates; cord blood transplants; unrelated transplants
Introduction
In 1990, the European Group for Blood and Marrow Transplantation (EBMT) introduced the activity survey as a novel instrument to capture comprehensive information on transplant numbers and to distribute this information rapidly. 1 All EBMT members and affiliated teams report since then on an annual basis their number of patients transplanted by indication, stem cell source and donor type. By now, it has evolved as a mandatory self-reporting system and forms an integral part of the comprehensive quality assurance program Joint Accredition Committee of the ISCT and EBMT (JACIE) (http://www.JACIE.org). It provides the basis for counseling on the individual patient level as well as for health-care institutions and administrative agencies in the field of stem cell transplantation. 2 Besides a report of the data from the past years, the activity survey has focused each year on a different aspect of hematopoietic stem cell transplantation (HSCT). This includes the description of trends, the introduction of new techniques or the changes in techniques as well as the analysis of economic factors related to HSCT. [3] [4] [5] [6] In 2006, the focus was on the use of cord blood as stem cell source. 7 The first report of a successful cord blood transplant for a patient with Fanconi's anemia gave the basis for the building of cord blood banks all over the world. 8 By 2007, nearly 300 000 cord blood products are available for use together with the more than 11 million unrelated donors from the 75 stem cell donor registries worldwide (www.bmdw.org). Carefully conducted retrospective analyses have confirmed the value of cord blood transplants under well-defined conditions compared to other family donor transplants or unrelated transplants. [9] [10] [11] [12] [13] [14] [15] The present report gives now most recent information on the use of cord blood transplants in Europe in 2006 within the context and in comparison with other stem cell sources.
Patients and methods

Data collection and validation
Participating teams reported their data for 2006 by indication, stem cell source and donor type as listed in Table 1 . Data were validated by three independent systems: through confirmation by the reporting team, which received a computer printout of the entered data; by selective comparison with MED-A data sets in the ProMISE data capture system of the EBMT (www.msbi.nl/Promise) and by cross-checking with national registries where they exist. Onsite visits of selected teams were part of the quality control program (www.jacie.org).
Teams
In total, 615 active transplanting teams in 43 countries (38 European and 5 affiliated countries) were contacted for the 2006 report, of which 605 reported their numbers. This corresponds to a 98% return rate of active teams and includes 498 active EBMT member teams reporting to the survey. Ten teams known by the investigators to have been performing HSCT in 2006 were also contacted, but chose not to reply or, for unknown reasons, failed to reply in spite of several efforts to reach them. No major transplant team in Europe is missing from this list. All contacted teams are listed in the Appendix in alphabetical order according to country, city and EBMT center code. We received information that in 2006 no blood or marrow transplants were performed in the following European countries: Albania, Andorra, Armenia, Georgia, Liechtenstein, Malta, Moldavia, Monaco, San Marino and The Vatican. NonEuropean countries include, by EBMT tradition, Algeria, Iran, Israel, Saudi Arabia, South Africa and Tunisia. Their data are in part included in some of the analyses.
Definitions
Transplant numbers. The EBMT survey focused, as in previous years, on the number of patients treated for the first time with HSCT. Information on additional transplants, for instance, a second, third or fourth HSCT in a patient with a previous HSCT was collected by disease category only for those patients with a planned double allogeneic after autologous transplants; for all other situations this information was collected generically only. The following definitions were used: 16 Re-transplants (autologous or allogeneic) were defined as an unplanned HSCT for rejection or relapse after a first HSCT. Multiple transplants were defined as being part of a planned double or triple autologous or allogeneic transplant protocol. Information on stem cell source was collected as bone marrow, peripheral blood or cord blood. Combined bone marrow, peripheral blood and cord blood transplants were reported as peripheral blood HSCT. The possibility for reporting cord blood transplants by indication and donor type was introduced for the first time in this year's survey. Information on reduced intensity conditioning was collected as a total for each team only and not for individual transplants. Definitions for reduced intensity conditioning (RIC) HSCT followed the recently published definitions.
Transplant rates. Transplant rates were computed as number of HSCT per 10 million inhabitants as previously defined. 2 Transplant rates refer to the number of transplants in a given country compared to its own population. The survey cannot make adjustments for patients who cross borders and receive their HSCT in a foreign country. Population data were obtained from the US census office (http://www.census.gov).
Economic factors. Economic factors considered in the analysis followed the previously defined rules. Countries were categorized by their gross national income per capita according to the World Bank definitions into high-income (Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Netherlands, Norway, Portugal, Slovenia, Spain, Sweden, Switzerland and UK), middle-income (Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland and Slovakia) and lowincome countries (Azerbaijan, Belarus, Bosnia and Herzegovina, Bulgaria, Macedonia, Romania, Russia, Serbia and Montenegro, Ukraine and Turkey). The latter category refers to the World Bank definition of 'lower middle income' (http://www.worldbank.org) as previously used.
Non-European countries that traditionally participate in the EBMT activity survey (Algeria, Iran, Israel, Saudi Arabia, South Africa and Tunisia) are included in the overall data presentation. They were not included in the analysis on economic factors. The same applies to Iceland and Luxemburg, because of some missing data over the time span. 
Results
Participating teams
Additional transplants 2006
There were 1557 re-transplants (772 allogeneic/785 autologous) and 2133 additional planned multiple transplants (71 allogeneic/2062 autologous). Thus, there were a total of 28 740 HSCT procedures; 10 504 allogeneic (37%) and 18 236 autologous (63%) transplants were performed in 2006. This corresponds to an overall increase of 93 retransplants (74 allogeneic and 19 autologous) or 6% as compared to 2005. Regarding the planned double autologous-allogeneic HSCT, there were a total of 531 procedures. Compared to 2005, when there was a total of 671 planned double autologous-allogeneic HSCT, this corresponds to a decrease of 21%. Main indications for the planned double transplant programs were, as in the previous year, multiple myeloma, non-Hodgkin's lymphoma and Hodgkin's disease. [17] [18] [19] [20] Transplant rates in 2006. There were marked differences in transplant rates between European countries and countries affiliated with EBMT as presented in Figure 1 .
These differences relate to all transplants (Figure 1a ), to allogeneic HSCT ( Figure 1b ) and to autologous HSCT ( Figure 1c ). Differences between Eastern and Western European countries have been previously reported. Of interest to note is that countries with similar total transplant rates had similar transplant rates for allogeneic HSCT as well as for autologous HSCT.
Disease indications
Indications for HSCT in 2006 are listed in detail in Table 1 . Main indications were lymphoproliferative disorders with 14 169 patients (56%), 1597 patients with allogeneic HSCT (Table 1) . Of the 9661 allogeneic first transplants, 24% were bone marrow, 71% were peripheral blood and 5% were cord blood transplants ( Figure 2 ). This corresponds to a slight decrease in the proportion of peripheral blood as stem cell source compared to the 74% in 2005. The proportion of peripheral blood as stem cell source varied depending on donor type. It was 72% for HLA-identical sibling donor transplants, 67% for unrelated donors, 81% for HSCT from other family members and, 74% for twin donors. Within allogeneic HSCT, the only disease indications with more bone marrow than peripheral blood donors as stem cell source were bone marrow failure syndromes (57% bone marrow) and congenital disorders (58% bone marrow) (Figure 2a ). The proportion of main indications varied as well within the three stem cell sources. Non-malignant disease represented about a quarter of all indications for bone marrow and cord blood, but only a small fraction among the peripheral blood transplants (Figure 2b ).
Donor type
For the 9661 allogeneic first transplants, HLA-identical siblings were used as donors for 4838 (50%) of the recipients, other family members for 539 (5.5%) of the recipients, a syngeneic twin for 43 (0.5%) of the recipients and an unrelated volunteer donor for 4241 (44%) of the recipients. They were used in 34% of all allogeneic HSCT. This information is collected only in a generic way; no information on disease distribution is possible by the activity survey.
Cord blood transplants
A total of 544 allogeneic HSCT were cord blood transplants compared to 395 in 2005, 283 in 2004 and 86 in 1997 when this item was introduced into the activity survey. The development over the last 10 years, and the massive increase in the last four years, is illustrated in Figure 3 . This increase was largely observed in countries of the high-income World Bank category. Of the 507 cord blood HSCT reported as first transplants, the majority, 458 (90.5%), were from unrelated donors. There were 45 (9%) HLA-identical and 4 (0.5%) non-identical family transplants. There were no autologous cord blood transplants reported. Overall, the 544 cord blood transplants correspond to 5% of all allogeneic HSCT. However, there were marked differences in the use of cord blood depending on disease indication (Table 2 ). Of the 507 cord blood HSCT reported by indication, a higher proportion was for non-malignant disorders (total 11%), specifically for congenital bone marrow failure syndromes (7%), immune deficiencies (15%) or inherited disorders of metabolism (27%). Cord blood was rarely used for solid tumors (4%) and lymphoproliferative disorders (2%). Cord blood was used more frequently in advanced leukemias than in early leukemia's. There were also major differences in the use of cord blood HSCT between the European countries. This refers to absolute numbers compared to the population (cord blood transplant rates) (Figure 4 ) as well as to the proportion of cord blood as stem cell source among the allogeneic HSCT (data not shown).
Donor lymphocyte infusions
There were 1920 patients reported as having received donor lymphocyte infusions in 2006. This corresponds to about two-thirds of the number of reported patients with RIC HSCT. No information on the disease indication of those patients with DLI is available from the activity survey.
Major changes over the last decade Allogeneic HSCT. The ongoing increase in allogeneic HSCT continued at the same rate as has been observed over the last decade for almost all indications ( Figure 5 ). Clear increases were seen in the acute leukemias, as illustrated for AML (Figure 5a ) and ALL (Figure 5b ). There were stable numbers for CML and lymphoproliferative disorders when compared to 2005.
Autologous HSCT. In contrast to the development in allogeneic HSCT, numbers in general remained stable for autologous HSCT overall ( Figure 6 ) as illustrated for plasma cell disorders (PCD) (Figure 6a) . However, the continuing decline in autologous HSCT for ALL is still evident (Figure 6b ).
Discussion
This report presents the current state of the art of HSCT in Europe in 2006. It documents the diversity of the procedure, which includes autologous and allogeneic stem cells from the three main sources, bone marrow, peripheral blood and cord blood for a broad range of malignant and non-malignant disorders. 21 Allogeneic HSCTs continue to increase for most indications in all countries and in countries with high and middle income by World Bank categories. This increase is most pronounced in patients with acute leukemia and is observed in related and unrelated HSCT as well. In contrast to allogeneic HSCT, numbers of autologous HSCT remained similar in most disease indications when compared to 2005.
For the first time since the introduction of the EBMT activity survey, detailed information was collected concerning cord blood transplants. The data confirm the increasing use of cord blood in general. They permit a rapid presentation of current use by indication and donor type. The data show marked differences in cord blood use between European countries. These differences are not explained solely by economic factors such as gross national income per capita or World Bank category. Most likely, these differences reflect the activities of the major cord blood banks in Europe and the impact of their leaders on the transplant activities with their countries.
There are a few notable findings. Cord blood is preferentially used for non-malignant, mainly congenital disorders. This reflects one selective advantage of cord blood. Its use is optimal in small children, which guarantees a high cell dose per kilogram body weight. It reflects as well the specific advantage of cord blood compared to other stem cell sources in the reduced incidence of GvHD. In 
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The most frequent use of cord blood overall was for acute leukemias. The rapid increase in use might be due to the introduction of new technologies, for example, the use of double cord blood products to increase the number of stem cells given or the use of combined haploidentical cord blood transplants. [22] [23] [24] [25] The survey does not provide data on these technologies; reports from the registries need to be analyzed to confirm this hypothesis. The fact that more cord blood HSCTs were used for advanced acute leukemias than for early leukemias might reflect this attitude and might reflect some of the reservations concerning general use of cord blood HSCT instead of an HLA-identical sibling or well-matched unrelated HSCT. It is also important to note that none of the teams reported an autologous cord blood HSCT in 2006.
As usual, the activity survey does not provide any outcome data. This is not the purpose of this data collection, whose focus is on the rapid dissemination of 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 1991 1992 1993 1994 1995 1996 1997 1998 1999 trends. Outcome data will be reported later and elsewhere. In contrast, this data give a clear overview on the status quo in 2006 and on the developments to be expected in the near future. As such, they provide a basis for patient counseling and health-care planning.
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